The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study
- PMID: 34455861
- PMCID: PMC8667790
- DOI: 10.1097/JU.0000000000002198
The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study
Abstract
Purpose: Premature ejaculation (PE) is one of the most common male sexual dysfunctions. Local anesthetics (LAs) and dapoxetine are frequently used to treat PE; however, previous studies show variable efficacy. This study aims to determine the efficacy of LAs and dapoxetine using a novel classification based on neurophysiological tests.
Materials and methods: This multicenter cohort study enrolled adult men (568) with an intravaginal ejaculatory latency time (IELT) ≤2 minutes. Patients were divided into 4 groups according to the results of neurophysiological tests and assigned different treatments for 12 weeks: 1) penile sensory hyperexcitability type (Sens)-LAs; 2) penile sympathetic hyperexcitability type (Symp)-dapoxetine; 3) mixed type (Mixed)-both LAs and dapoxetine; 4) normal type (Norm)-both LAs and dapoxetine. Self-estimated IELT and patient-reported outcomes were recorded.
Results: The total percentage of men achieving IELT >2 minutes and ≥5 minutes after treatment were 82.7% and 76.7%, respectively. For men with abnormal results of neurophysiological tests, 401 (86.6%) had improved IELT >2 minutes after the 12-week treatment course, in which 375 (81.0%) achieved IELT ≥5 minutes. All patient-reported outcome measures improved in each group after 12 weeks of treatment, with greater improvements among those with abnormal neurophysiological tests.
Conclusions: The efficacy of LAs and dapoxetine increased in PE patients with abnormal results of neurophysiological tests. This novel classification of PE using neurophysiological tests could help guide and improve efficacy of PE therapies.
Keywords: anesthetics, local; neurophysiological monitoring; premature ejaculation; serotonin uptake inhibitors.
Figures





Comment in
-
Editorial Comment.J Urol. 2022 Jan;207(1):189. doi: 10.1097/JU.0000000000002180.01. Epub 2021 Sep 30. J Urol. 2022. PMID: 34587772 No abstract available.
-
Editorial Comment.J Urol. 2022 Jan;207(1):181-182. doi: 10.1097/JU.0000000000002198.01. Epub 2021 Oct 5. J Urol. 2022. PMID: 34607448 No abstract available.
References
-
- Porst H, Montorsi F, Rosen RC, et al. : The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007; 51: 816. - PubMed
-
- Morales A Barada J and Wyllie MG: A review of the current status of topical treatments for premature ejaculation. BJU Int 2007; 100: 493. - PubMed
-
- Waldinger MD, Berendsen HH, Blok BF, et al. : Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998; 92: 111. - PubMed
-
- Carson C and Wyllie M: Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3179. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources